The Latest Cardiac and Vascular News
The favorable opinion of the CPP (French ethic committee) and authorization from the ANSM (French National Agency for the Safety of Medicines and Health Products) allow the operational launch of the HEART study. The HEART study will be conducted under […]
TOTUM-070 is being developed particularly for individuals with untreated hypercholesterolemia, with LDL-cholesterol levels up to 190 mg/dL associated with moderate overall cardiovascular risk. It responds to an unmet medical need for this population; TOTUM-070 has high potential in the market […]
TOTUM-070 exclusivity guaranteed in the United States and in Europe for reducing blood LDL-cholesterol levels, a cardiovascular disease risk factor; Intellectual property rights protecting the composition of the TOTUM-070 active substance for food and pharmaceutical applications; A milestone in the […]
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/ SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the acceleration of its pipeline clinical development, of plant-derived active […]
